Track 1: Drug Delivery Technology

Drug Delivery Conferences attains greater global significance as Drug Delivery plays an indispensable role in the future of the pharmaceutical research Novel drug delivery system is a mechanism by which a drug is delivered in such a way that it can reach the maximum level of efficacy. The conference includes topics like Lipid Polymers to enhance drug delivery technology by providing controlled release of therapeutic agents in constant doses over long periods, cyclic dosage, and methodical release of both hydrophilic and hydrophobic drugs. In vitro and in vivo dissolution testing is required to ensure that the drug dissolves at a steady and consistent rate in batch to batch of formulated drug product. The dissolution rate of poorly soluble drugs can be increased by dissolving them in liquid hydrophilic vehicles followed by soaking on highly porous materials. The major objective is to deliver an innovative speech on the latest Targeted drug delivery method for providing medication to a patient in a manner which increases the concentration of the medication in some parts of the body relative to others. Pharmacokinetic behavior in drug design and drug development for safety issues arise either as a result of animal toxicity testing or in the clinical program itself

Track 2: Novel Drug Delivery Systems

For the target of amplifying knowledge on the current researchers on developing drug delivery systems via novel techniques for Pharmaceutical formulation development, Drug Delivery conference is centred around quality topics including Liposomes, Dendrimer, Targeted Drug Delivery design, versatile polymer in Drug Delivery and Controlled Drug Delivery, Trans mucosal Drug Delivery, Blood Brain Barrier, Optimization of pharmaceutical products, Sustained Drug Delivery Systems, are an uniquely architectured session which plays an important role in the fields of pharmaceutical formulation development and Pharmacology.

Track 3: Routes of Drug Administration

Aimed and specially designed session for young and senior researcher from academic on drug dosage formulations through novel routes in drug delivery where researcher interested for developing novel routes to minimize drug interactions occur through common routes by which a drug is brought into contact with the body. Different dosage forms are manufactures by pharmaceutical companies according to drug designing to maximize bioavailability. Session includes different routes of administration like Topical drug delivery via a large range of classes including but not limited to creams, foams, gels, lotions, and ointments. Pulmonary drug delivery system route is gaining much importance in the present day research field as it enables to target the drug delivery directly to lung both for local and systemic treatment. Nasal drug delivery an alternative route restricted to intravenous administration this area has been widely investigated in recent years by academics. Topics like other novel routes wise Vaginal drug delivery covers self-insertion creams, foams, gels, irrigations and tablets, are known to reside in the vaginal cavity. Oral Drug Delivery routes to reaching different parts of the body via the bloodstream. Injectable formulations intended for administration by injection, infusion or implantation and placental development into the body.

Track 4: Pharmaceutical Nanotechnology

Pharmaceutical Nanotechnology for Drug Delivery using Nanotechnology session plays major role in the future of pharmaceutical research. In this session, we will go over several of the most important features of nanotechnology, anticancer drug development , pharmocology of cancer drugs, that will impact our lives but we will also talk about what nanotechnology itself will be like in the future and Investigator specifically from cancer therapy. Interestingly pharmaceutical sciences are using nanoparticles to reduce toxicity and side effects of drugs and up to recently did not realize that carrier systems themselves may impose risks to the patient. Nano technology session includes drug delivery using nanotechnology, Pharmaceutical technology, Nanoparticles permeability to BBB, Cancer drug targets, Nanoparticles application, Pancreatic Cancer, Nanoliposome-mediated delivery, MicroRNA therapeutics, recent breakthroughs in nanoparticle design to demonstrate their high potential as multifunctional drug delivery nanocarrier, Carriers for nanotechnology, various nanostructures, magnetic nanoparticles. In this review Polymer Nanotechnology for Drug Delivery, Nano composite materials, to deliver highly efficient therapeutic compounds to patient a future aspect of Nanotechnology has a vast future ahead of it and we are constantly making breakthroughs in this industry every day. 

Track 5: Nucleic Acid Based Drug Delivery

Nucleic acids science and technologies experience tremendous progress and changes. The conference will feature prominent experts discussing latest advances in nucleic acids, industrial pharmacy, pharmaceutical design, drug targeting,  anticancer drug development , Nano pharmaceutics,  research and development: TNA for treating cancer and viral diseases in the near future for drug delivery includes novel Rnai-Based Therapy, advances in siRNA delivery, oligonucleotide drug delivery, viral gene therapy and Artificial microRNAs, non-coding RNA (miRNA, piRNA, lncRNA, and lincRNA) this architect session to play an important role in the fields of cancer targeting and pharmaceutical nanotechnology.

Track 6: Smart Drug Delivery Systems

To maximize knowledge of the current researcher on developing drug delivery via Pharmaceutical formulation, Smart Drug Delivery conference themed quality topics on Drug Targeting, Drug Designing, Drug evaluation, Drug Delivery and Therapeutics, Biodegradable polymers, Dendrimer a versatile polymer in drug delivery are a uniquely architect session to play an important role in the fields of nanotechnology, pharmaceutical and medicinal chemistry. Major drugs driving growth of the overall smart drug delivery market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex

Track 7: Vaccine Based Drug Delivery Technology

Vaccine is multidisciplinary scientific field that is currently undergoing rapid development. An important component of cancer vaccines is the development of novel vaccine strategies, this session includes Laser technology for Vaccine Adjuvants, Challenges and opportunities For Vaccine Delivery, These advances promise to accelerate the development and testing Jet injectors, micro needles, Needle free drug delivery technology, is an innovative technique to deliver drugs into a person's body without piercing their skin.

Track 8: Drug Delivery Companies and Markets

Drug Delivery Companies and Market session is beginning to change for small, medium, and large scale pharmaceutical Co, biopharmaceutical Manufacturing and Industries ,  generic drugs companies, contract drug delivery companies which can manifest from development to manufacturing. Addressing these instabilities is a great challenge, because of the complexity of the Clinical bio therapeutics themselves. This session includes Rheological behavior, Pharmaceutical Guidelines, Pharmaceutical companies and regulatory guidelines perspectives, Advances in computational modeling for bioavailability, drug Stability of Pharmaceutical products which are driving crucial research into new vaccines and medicines. The pharmaceutical industry and the public sector are thinking differently than before about how to improve access to medicines and advance research and development for neglected diseases.

Track 9: Bio therapeutics as Novel Technique in Drug Delivery

As new product formats progress through development and into the regulatory process, the role of Bio therapeutics as Novel Technique in Drug Delivery is important scope. The demand for Biopharmaceuticals manufacturing and industry is continuously increasing, because many Therapeutic Agents are reaching later stage clinical trials. Most bio therapeutic drugs are recombinant monoclonal antibodies which are widely produced in mammalian cell lines because of the need for post-translational modifications that should be alike or at least similar to those obtained in humans. Thus, there is an increase in the market for cell line development. Moreover, advancements in upstream processing technologies have led to improvement in speed and efficiency of generating robust and highly productive cell line for large scale production of protein therapeutics and has propelled the market for cell line development. Major drugs driving growth of the overall smart drug delivery market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza,  Zoladex, Beckton Dickinson & Company (U.S.), Beckman Coulter (U.S.), Boehringer Ingelheim Group (Germany), Catalent Inc. (U.S.), CMC Biologics A/S (Denmark), Lonza Group Ltd. (Switzerland), EMD Millipore (U.S.), Partec (Sysmex Corporation) (Japan), ProBioGen AG (Germany), Selexis SA (Germany), Sigma-Aldrich Co. LLC.

According to a New Market Research “Bio therapeutics as Novel Technique in Drug Delivery Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2022”, the Bio therapeutics as Novel Technique in Drug Delivery was valued at US$56.03 mn in 2015 and is anticipated to expand at a CAGR of 7.5% from 2015 to 2022 to reach US$99.84 mn by 2022.

Track 10: Drug Delivery and Device Development

In this session we will focus on Medical Devices designed for drug delivery through the pulmonary and nasal routes. These routes are of interest for local delivery, as in asthma, but also for rapid delivery of drugs to the system circulation and direct delivery to the central nervous system. Devices that account for specific anatomical and physiological features of the intranasal and pulmonary routes will be featured.  Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a specific route of administration. Such devices are used as part of one or more medical treatments. Many in the industry have long felt overly burdened by what they consider to be an unnecessarily complex approval process. Critics claim it impedes innovation and delays the availability of better health care. To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other nonprofit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.

Current research on femtosecond laser microfabrication of fluidic devices is introduced to present their research to elaborate. The research on microfluidics provides highly sensitive microfluidic sensors for practical applications with significant advantages of portability, efficiency, sensitivity, versatility, and low cost.

Track 11: Recent Advances in Drug Delivery

The scope of this session on research in Recent Advances in Drug Delivery includes

Opportunities and challenges for Drug Delivery Market in the Pharmaceutical analytical Market to forecasts for Drug Delivery Market in the global Pharmaceutical companies from 2009 to 2025. Sessions includes solid pharmaceutical Drug Dosage Formulations, drug bioavailability, Tumor targeting, Tumour Biomarkers, coating materials. The key geographies including the US, Europe, Japan and Emerging Hotspots such as India, Singapore and ChinaTechnology trends in Drug Delivery Market that shape the industry Qualitative analysis of the market drivers, barriers, future outlook and challenges for the Drug Delivery Market Analysis of competitive landscape and the leading market players.

Track 12: Major challenges in Drug Delivery

By focusing on Major challenges in Drug Delivery in the drug-delivery technology market

Session includes: Reducing Patient Compliance, Drug Delivery of poorly soluble drugs, Overcoming challenges in pediatric drug delivery, controlling the addictive nature of drugs, Polymeric enhancement.

There is an increasing demand for effective and, ideally, non-invasive drug-delivery methods. This is especially the case for the biopharmaceutical sector, which has experienced an overwhelming growth due to advances in biotechnology. In 2009, over $12 billion were invested in biologics / biotechnology research and development (R&D), representing a 26% share in the total R&D expenditure. A recent report by the Pharmaceutical Research and Manufacturers of America (PhRMA) states that in 2015 there were 901 biological in development, targeting more than 100 diseases.

Track 13:  Peptide and Protein Drug Delivery

This session and track is intended to assist pharmaceutical scientists in the development of stable Medicinal Preparations of Proteins and Peptides during the early stages of the product development process for Pharmaceutical technology providing a comprehensive review of mechanisms and causes of protein instability in formulation development, coverage of accelerated stability testing methods and relevant analytical methods, and an overview of the drug substance manufacturing process. Preformulation and the development of traditional solutions and lyophilized formulations frequently used for intravenous delivery and non-traditional formulations are also addressed.

The drug delivery technology market is expected to reach USD 1,504.7 Billion by 2020 from USD 1,048.1 Billion in 2015, growing at a CAGR of 7.5% from 2015 to 2020. Factors such as rising prevalence of chronic diseases, growth of the biologics market, new product launches, and drug innovation and technological advancements are driving the growth of this market. On the other hand, patent expiry and patent cliff, increase in the injuries and side effects are hindering the growth of this market.

Track 14:  Drug Delivery Equipment and Machinery

Equipment and Machinery for Drug Delivery session includes major area participants/ Vendors, Engineers in Equipments from Laboratory equipments, Analytical Equipments, Auto Injectors, Semi-Automatic R&D Equipment, Large volume Production Machineries and Drug Delivery Pilot Equipments.

Track 15: Business Opportunities in Drug Delivery

The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S. constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% for 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists. Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, quality control, and business development Business opportunities in drug delivery.

Societies and Assosiation

Congress on Innovation in Drug Delivery (APGI), Controlled Release Society (CRS), International Society for Aerosols in Medicine (ISAM), The Pharmaceutical and Healthcare Sciences Society (PHSS).

The global drug delivery technology market is predictable to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% through the forecast period. Growing frequency of chronic diseases, increasing demand for biologics, technological advancements and new product introductions are some of the key factors driving the progress of the market.

This market is subdivided based on route of administration, facility of use and region.

Based on route of administration, the market is subdivided into oral, injectable, topical, nasal, ocular, pulmonary, implantable and transmucosal. In 2016, the oral drug delivery segment is likely to account for the major share of the market. Based on facility of use, the market is subdivided into the hospitals, ambulatory medical centers/clinics, home care settings, diagnostic centers and other facilities of use. In 2016, the hospitals segment is probable to account for the prime part of the market.

Based on region, the market is subdivided into North America, Europe, Asia and the Rest of the World. Market is conquered by North America. Asia is likely to rise at the highest CAGR through the forecast period. Chances in the Asian market have attracted vast investments by main companies in the area of R&D activities.

Prominent performers in the drug delivery technology market include Johnson & Johnson, Inc. (U.S.), F. Hoffman-La Roche (Switzerland), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Bayer AG (Germany), Becton, Dickinson and Company (U.S.), GlaxoSmithKline plc, (U.K.), Pfizer, Inc. (U.S.), Sanofi (France), 3M Company (U.S.), and Antares Pharma, Inc. (U.S.).

Letter of Invitation

It's the delegate's responsibility to investigate the visa requirements for Canada and to apply for a visa, if necessary. Individuals requiring an official Letter of Invitation from the conference organizers can request one by email by writing to us at drugdelivery@annualamericacongress.org

To receive a Letter of Invitation, delegates, accompanying persons/children, student/post-doc/youth delegates and exhibitors must first register for the conference.

The registration fee minus a handling fee of USD 100 will be refunded after the conference if the visa was applied for in time and proof is shown that a visa could not be granted even though all requested documents were submitted.

All expenses incurred in relation to the conference are the sole responsibility of the delegate. The Letter of Invitation does not guarantee an entry visa to Canada. However, the conference organizers will not directly contact embassies and consulates on behalf of delegates.

The deadline for requesting a Letter of Invitation is one month before traveling to Canada.